50.07 0.00 (0.00%)
After hours: 4:54PM EDT
|Bid||49.97 x 1400|
|Ask||50.13 x 2200|
|Day's Range||49.66 - 50.53|
|52 Week Range||42.48 - 63.69|
|Beta (3Y Monthly)||0.59|
|PE Ratio (TTM)||13.19|
|Earnings Date||Oct 31, 2019|
|Forward Dividend & Yield||1.64 (3.29%)|
|1y Target Est||58.13|
Giovanni Caforio has been the CEO of Bristol-Myers Squibb Company (NYSE:BMY) since 2015. This analysis aims first to...
Traders also look at the activity of short sellers for trading opportunities. Sometimes, stocks with a large amount of short selling activity could be potential candidates for short squeezes. Other times, ...
Bristol-Myers Squibb today was upgraded to buy by TheStreet.com's quantitative service. Let's see whether the technical analysts and the quants are in agreement. In the daily bar chart of BMY below, prices appear to have been hammering out a base pattern.
Overall survival data from CheckMate -227 Part 1 evaluating Opdivo plus low-dose Yervoy in advanced non-small cell lung cancer featured in ESMO Presidentia
The FDA assigns a Fast Track status to AstraZeneca's (AZN) Farxiga to reduce the risk of cardiovascular death or worsening of heart failure in adult patients with HFrEF and HFpEF.
Roche's (RHHBY) immuno-oncology drug, Tecentriq, meets the primary goal in a late-stage study in NSCLC patients. Also, the company reports positive data on its NMOSD drug in a phase III study.
Zacks Market Edge Highlights: UnitedHealth, Centene, MasTec, Bank of America and Bristol-Myers Squibb
Roche's (RHHBY) immuno-oncology drug, Tecentriq, meets the primary goal in a late-stage study in NSCLC patients. Also, the company reports positive data on its MS drug in a phase III study.
Year to date, the performance on Wall Street is projecting a glorious picture with no end to the bull run in sight, at least this year.
Bristol-Myers Squibb Company will announce results for the third quarter of 2019 on Thursday, October 31, 2019. During a conference call at 8:30 a.m. ET on October 31, company executives will review financial information and will address inquiries from investors and analysts.
The Board of Directors of Bristol-Myers Squibb Company today declared a quarterly dividend of forty one cents per share on the $.10 par value Common Stock of the corporation.